The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Cancer clinical trials shouldn’t discriminate—but they do

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Erin Miller
Development manager, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
By Jamillah Hoy-Rosas
Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels. 
Byline
Erin Miller
Development manager, Lazarex Cancer Foundation
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account